Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HealiusASX:HLS +5.26%47 Debt-to-Equity is 1.69 as of Dec. 2025, which is 86% above its 10-year median of 0.91. GuruFocus rates ASX:HLS with a GF Score™ of 47/100 and a GF Value™ of A$1.02 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Healius ranks worse than 90.16% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Healius's Debt-to-Equity or its related term are showing as below:
ASX:HLS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.37 Med: 0.91 Max: 1.69
Current: 1.69
During the past 13 years, the highest Debt-to-Equity Ratio of Healius was 1.69. The lowest was 0.37. And the median was 0.91.
ASX:HLS's Debt-to-Equity is ranked worse than 90.16% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.33
vs ASX:HLS: 1.69
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Healius Debt-to-Equity Related Terms
Healius Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Healius's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:HLS vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Healius's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healius Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Healius's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Healius's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healius (ASX:HLS) has a Debt-to-Equity of 1.69 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Healius and its competitors. This is 86% above median its historical median of 0.91. Over the past decade, Healius' Debt-to-Equity has ranged from 0.37 to 1.69. According to the industry distribution chart, Healius ranks #165 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 90.2%.
Is Healius' Debt-to-Equity too high?
Healius' current Debt-to-Equity of 1.69 is 86% above median its 10-year median of 0.91. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 1.69. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Healius' value of 1.69 is 412.1% above this industry median. Based on the distribution chart, Healius ranks #165 out of 183 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Healius has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Healius' Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Healius ranks #165 out of 183 companies for Debt-to-Equity. This places Healius in the lower half of its industry. The industry median Debt-to-Equity is 0.33. Healius' value of 1.69 is 412.1% above this benchmark. Historically, Healius' own Debt-to-Equity has ranged from 0.37 to 1.69 over the past decade. While the company's 10-year median is 0.91 vs. the industry median of 0.33, Healius has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healius's current Debt-to-Equity of 1.69 is 412.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Healius and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healius's current Debt-to-Equity is 1.69, which is 86% above median its own 10-year median of 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healius stock overvalued right now?
Based on GuruFocus' analysis, Healius (ASX:HLS) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.02, compared to a current price of A$0.40 — trading 60.8% below its estimated fair value. The current Debt-to-Equity is 1.69, which is 86% above median its 10-year median of 0.91 and 412.1% above the Medical Diagnostics & Research industry median of 0.33. Healius' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Healius (ASX:HLS), the current Debt-to-Equity is 1.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healius (ASX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, Healius stock appears to be undervalued.
The current stock price of A$0.40 is trading 60.8% below its estimated GF Value™ of A$1.02.
GuruFocus considers Healius to be Possible Value Trap.
Key valuation signals for ASX:HLS:
Debt-to-Equity: 1.69 (86% above median its 10-year median of 0.91)
GF Value™: A$1.02 vs. price of A$0.40 (60.8% below fair value)
Industry Position: 412.1% above the Medical Diagnostics & Research median (#165 of 183)
No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
47GF Score
Get the complete analysis for ASX:HLS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HLS has been successfully added to your 
